DENVER, CO--(Marketwire - June 24, 2009) - Dr. Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board of Omni Bio Pharmaceutical, Inc. ("OMNI") (OTCBB: AAFS)

In October 2008, Dr. Lewis co-published a study in the Proceedings of the National Academy of Sciences with OMNI Acting Chief Executive Officer Dr. Charles A. Dinarello and University of Colorado researcher Dr. Leland Shapiro titled "Alpha-1-Antitrypsin Monotherapy Induces Immune Tolerance During Islet Allograft Transplantation in Mice."

Dr. Lewis joins Dr. James Crapo and Dr. Michael Iseman, both physicians at National Jewish Health in Denver, and Dr. James Mier of Dana-Farber Harvard Cancer Center and Beth Israel Deaconess in Boston, on the Scientific Advisory Board of OMNI.

OMNI is the licensee of filed patents from the University of Colorado related to the treatment of graft rejection and transplantation using alpha-1 antitrypsin. The Company plans to conduct further research into the use of alpha-1 antitrypsin for the treatment of islet transplantation, and pursue commercialization of the Company's intellectual property upon the receipt of the proper regulatory approvals.

About Ben-Gurion University of the Negev

Ben-Gurion University of the Negev is a world-renowned institute of research and higher learning with campuses in Beer Sheva and Eilat, Israel. Ben-Gurion University plays a vital role in Israel in fulfilling its unique responsibility to advance science and technology, to develop the Negev, reach out to its local community as well as its Arab neighbors, and share its expertise with the world.

About Ben-Gurion University of the Negev American Associates

American Associates, Ben-Gurion University of the Negev (AABGU) is a partner in Ben-Gurion University's mission. Founded in 1972, AABGU is a nonprofit corporation with headquarters in New York City and nine regional offices throughout the United States. AABGU raises funds and awareness for Ben-Gurion University of the Negev (BGU).

About Omni Bio Pharmaceutical, Inc.

Omni is the licensee of issued and pending patents from the University of Colorado Denver. Omni has been advancing broad-spectrum therapeutics targeting bacterial and viral diseases, biohazards, diabetes and transplant rejection since February 2006. The Company's core technology is based on novel discoveries made at the University of Colorado involving therapeutic agents already approved for use in humans.

Regarding Forward-Looking Statements

Statements in this document regarding future financial, scientific or operating results, future development programs, the development and commercialization of new supplier, partner or customer contracts, the commitment of suppliers and future opportunities for any of the companies mentioned herein, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not statements of historical fact (including but not limited to statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: variations in results of animal or human clinical trials, engineering and material costs, development costs, the availability of future financing on terms that are acceptable to any of the companies mentioned herein, other general costs and expenses; the ability to retain key personnel; the company's ability to successfully execute its business strategies; the levels and availability of government sponsored research programs including possible funding from the Project Bio-Shield Act of 2004 and the Pandemic and All Hazards Act of 2006; lack of commercial revenues; delays in the possible development of a commercial market for products due to FDA restrictions or requirements to increase our levels of clinical testing; our reliance on a limited number of suppliers for raw materials used in products; shortages of raw materials; competitive conditions in the industry; business cycles affecting the markets in which any of the companies mentioned herein conducts business; and economic conditions generally.

Additional risk factors may be found in the company's Form 8-K filed April 6, 2009 and in other documents filed with the U.S. Securities and Exchange Commission.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management as of the date of this press release, and the companies mentioned herein, does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.